- Home
- FBP vs RCUS Comparison
FBP vs RCUS Comparison
Compare FBP & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBP | RCUS |
|---|---|---|
| Founded | 1948 | 2015 |
| Country | United States | United States |
| Employees | N/A | 601 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 2010 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FBP | RCUS |
|---|---|---|
| Price | $28.82 | $28.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $25.50 | ★ $31.90 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 18.78 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $1,255,034,000.00 | $247,000,000.00 |
| Revenue This Year | $15.10 | N/A |
| Revenue Next Year | $4.65 | $45.62 |
| P/E Ratio | $50.61 | ★ N/A |
| Revenue Growth | ★ 2.38 | N/A |
| 52 Week Low | $19.16 | $8.84 |
| 52 Week High | $28.93 | $31.74 |
Technical Indicators
Market Signals| Indicator | FBP | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 74.76 | 51.38 |
| Support Level | $19.43 | $20.20 |
| Resistance Level | N/A | $28.72 |
| Average True Range (ATR) | 0.51 | 1.33 |
| MACD | 0.15 | -0.16 |
| Stochastic Oscillator | 92.99 | 50.83 |
Price Performance
Historical ComparisonAbout FBP First BanCorp. New
First BanCorp is a financial holding company. The company's operating segment includes Mortgage Banking; Consumer (Retail) Banking; Commercial and Corporate Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. The Consumer (Retail) Banking segment generates the majority of revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.